Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Sangamo Therapeutics Inc. Stock

Price
Target price
€0.48

€0.48

7.500%
0.0345
7.500%
€2.79
 
19.04.24 / Tradegate WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Wizard

Sangamo Therapeutics Inc. Stock

Sangamo Therapeutics Inc. dominated the market today, gaining €0.035 (7.500%).
With 11 Buy predictions and 12 Sell predictions the community is currently undecided on Sangamo Therapeutics Inc..
However, we have a potential of 316.49% for Sangamo Therapeutics Inc. as the target price of 2 € is above the current price of 0.48 €.
For the coming years our community has positive and negative things to say abot the Sangamo Therapeutics Inc. stock. Criterium "Unique positioning" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
What does Sangamo Therapeutics do?

Pros and Cons of Sangamo Therapeutics Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Sangamo Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sangamo Therapeutics Inc. 7.500% -7.369% -31.380% -67.832% -16.501% -94.888% -95.400%
Ardelyx Inc. -2.180% -8.082% -17.622% 36.376% 5.467% -17.061% -
Salarius Pharmaceuticals Inc. 1.850% 7.843% -16.981% -69.863% -20.721% -98.138% -99.994%
Evolus Inc -1.830% -4.386% -15.504% 39.744% 16.578% 23.164% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Sangamo Therapeutics, a company in the Biotechnology & Medical Research industry with the US symbol SGMO, has displayed a mixed financial performance over the past few years. The company's financial statements show some strengths and areas of concern. A detailed analysis of Sangamo Therapeutics' financials reveals the following pros and cons:

*Pros: *

Revenue Growth: Sangamo Therapeutics has experienced revenue growth over the last three periods, demonstrating its ability to generate higher sales. This is a positive sign for the company as it shows market demand for its products and services.

Show more

Comments

Prediction Buy
Perf. (%) -37.90%
Target price 4.606
Change
Ends at 19.03.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.
Ratings data for SGMO provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
19.03.24
Prediction Buy
Perf. (%) -37.71%
Target price 2.759
Change
Ends at 18.03.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
18.03.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Show more

StockNews.com 
0
Report Share
13.02.24 Sell -31.29%
Show more
Not a member yet? Sign up for free!

News

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the

BusinessWire_EN 
0 22.03.24
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data

BusinessWire_EN 
0 13.03.24
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid variant, STAC-BBB, that demonstrated

BusinessWire_EN 
0 13.03.24